AU2012318275B2 - Use of C1-inhibitor for the treatment of secondary edema of the central nervous system - Google Patents

Use of C1-inhibitor for the treatment of secondary edema of the central nervous system Download PDF

Info

Publication number
AU2012318275B2
AU2012318275B2 AU2012318275A AU2012318275A AU2012318275B2 AU 2012318275 B2 AU2012318275 B2 AU 2012318275B2 AU 2012318275 A AU2012318275 A AU 2012318275A AU 2012318275 A AU2012318275 A AU 2012318275A AU 2012318275 B2 AU2012318275 B2 AU 2012318275B2
Authority
AU
Australia
Prior art keywords
edema
stroke
inhibitor
subject
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012318275A
Other languages
English (en)
Other versions
AU2012318275A1 (en
Inventor
Gerhard Dickneite
Christoph Kleinschnitz
Bernhard Nieswandt
Marc Nolte
Ingo Pragst
Stefan Schulte
Guido Stoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2012318275A1 publication Critical patent/AU2012318275A1/en
Application granted granted Critical
Publication of AU2012318275B2 publication Critical patent/AU2012318275B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012318275A 2011-12-22 2012-12-21 Use of C1-inhibitor for the treatment of secondary edema of the central nervous system Active AU2012318275B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254 2011-12-22
EP11195254.5 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
AU2012318275A1 AU2012318275A1 (en) 2013-07-11
AU2012318275B2 true AU2012318275B2 (en) 2016-05-19

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012318275A Active AU2012318275B2 (en) 2011-12-22 2012-12-21 Use of C1-inhibitor for the treatment of secondary edema of the central nervous system

Country Status (10)

Country Link
US (1) US9452203B2 (OSRAM)
EP (1) EP2793935B1 (OSRAM)
JP (1) JP6127063B2 (OSRAM)
KR (1) KR102022231B1 (OSRAM)
CN (1) CN104080474B (OSRAM)
AU (1) AU2012318275B2 (OSRAM)
CA (1) CA2858984C (OSRAM)
DK (1) DK2793935T3 (OSRAM)
ES (1) ES2587863T3 (OSRAM)
WO (1) WO2013093027A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
KR102430453B1 (ko) 2013-03-15 2022-08-05 바이로파마 바이오로직스 엘엘씨 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
HK1259251A1 (zh) 2015-04-06 2019-11-29 Bioverativ Usa Inc. 人源化抗c1s抗体及其使用方法
ES2927271T3 (es) 2015-11-19 2022-11-03 Takeda Pharmaceuticals Co Inhibidor de esterasa C1 humana recombinante y usos del mismo
MY198182A (en) 2016-10-12 2023-08-09 Bioverativ Usa Inc Anti-C1s Antibodies and Methods of use Thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073186A2 (en) * 2005-12-21 2007-06-28 Pharming Intellectual Property Bv Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AKITA N. et al, Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model, Neurosurgery, 2003, Vol. 52, pg. 395-401 *
FRIESESKE S. et al, C1-Esterase-Inhibitor als Ultima-ratio-Therapie bei volumen- und katecholaminrefraktarem Schock infolge Ischamie-Reperfusionsschaden nach langer Reanimation, Intensivmed, 2002, Vol. 39, pg. 610-616 *
GESUETE R. et al, Recombinant C1 Inhibitor in Brain Ischemic Injury, Annals of Neurology, 2009, Vol. 66, pg. 332-342 *
LONGHI L. et al, C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice, Critical Care Medicine, 2009, Vol. 37(2), pg. 659-665 *
STORINI C. et al, C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation, Neurobiology of disease, 2005, Vol. 19, pg. 10-17 *
TEI R. et al, Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat, Neurological Research, 2008, Vol. 30, pg. 761-767 *

Also Published As

Publication number Publication date
CN104080474B (zh) 2016-04-27
JP6127063B2 (ja) 2017-05-10
US9452203B2 (en) 2016-09-27
US20140371425A1 (en) 2014-12-18
EP2793935A1 (en) 2014-10-29
CN104080474A (zh) 2014-10-01
DK2793935T3 (en) 2016-09-05
EP2793935B1 (en) 2016-05-25
HK1201729A1 (zh) 2015-09-11
CA2858984C (en) 2021-01-05
KR102022231B1 (ko) 2019-09-19
ES2587863T3 (es) 2016-10-27
JP2015502389A (ja) 2015-01-22
CA2858984A1 (en) 2013-06-27
WO2013093027A1 (en) 2013-06-27
AU2012318275A1 (en) 2013-07-11
KR20140107567A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
AU2012318275B2 (en) Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Kraft et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis
KR101956585B1 (ko) 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
KR100300798B1 (ko) 보체억제제를함유하는염증성장질환염증성피부질환및자반증의예방및치료용약제학적조성물
Mencl et al. FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation
US20240239883A1 (en) Methods of treating homologous recombination deficient cancer
JP2013527143A (ja) 間質性肺疾患を処置するための第ｘｉｉ因子阻害剤
Salman et al. Acute hyperglycemia exacerbates hemorrhagic transformation after embolic stroke and reperfusion with tPA: a possible role of TXNIP-NLRP3 inflammasome
JP7109160B2 (ja) 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
HK1201729B (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
Cirak et al. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm
US20230287430A1 (en) Use of pi3kc2b inhibitors for the preservation of vascular endothelial cell barrier integrity
US7375076B2 (en) Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
JP2006510620A (ja) 心筋梗塞の治療方法
CN111818938A (zh) 先兆子痫的治疗和预防
US20250144179A1 (en) Peptide hormone to prevent or treat vasospasm, brain injury or cerebral edema
Jin et al. Amelioration of Post‐Stroke Edema and Microcirculatory Dysfunction via Targeted AQP4 Inhibition While Preserving the Glymphatic System
Shanmugaiah et al. The efficacy of intracisternal irrigation of papaverine on cerebral blood flow in patients with subarachnoid hemorrhage
US20200062855A1 (en) Compositions and methods of promoting wound healing
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
Song et al. Up-regulation of TGF-β via the activation of extracellular signal-regulated kinase 1 and 2 induced by prorenin in human renal mesangial cells
S Hernandes et al. Hernandes et al., 2018. pdf
JP2016513131A (ja) 羊水塞栓の治療剤
Revill et al. Ecallantide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)